FRITS STULP
Managing director of Iperion – a Deloitte business, Amsterdam, the Netherlands

Abstract

Life Sciences organisations have had to rapidly adapt to a new landscape of operations. The challenges of the pandemic have put an urgent focus on enhancing patient outcomes by improving products delivery processes. In 2023 Life Sciences companies must develop strategies to capitalise on the opportunities that data-driven technologies offer. Frits Stulp of Iperion – a Deloitte business – predicts a new wave of data-based transformation as the drive to reduce time to market and address product shortages continues.

Last year was another challenging one for the Life Sciences industry. On top of residual pandemic-related challenges and supply chain issues, the ever-adapting Regulatory environment has continued to set new standards and enforce new requirements. Those companies that have managed to keep pace with the changes can expect to start reaping some of the rewards of their efforts over the coming year. Others still have work to do, but as new waves of digital transformation promise new process efficiency burdens should start to reduce and improved patient experiences will gradually become a reality.

Here’s a roundup of some of the most notable developments of the last year, and what’s likely to be a growing focus in 2023.

EMBEDDING CTIS PROCESSES
In terms of drug development and clinical trials, EU Clinical Trial Regulation and more specifically the Clinical Trial Information System (CTIS) presented one of the main practical changes of 2022, and the transition to the new registration system has begun in earnest now. From February this year all new clinical trials applications must be submitted via the new portal ...